ABBV 428

Drug Profile

ABBV 428

Alternative Names: ABBV-428

Latest Information Update: 09 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD40 ligand stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Nov 2016 Preclinical trials in Solid tumours in USA (IV) before November 2016 (NCT02955251)
  • 02 Nov 2016 AbbVie plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA (NCT02955251)
  • 01 Nov 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA (IV) (NCT02955251)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top